Bath additives for the treatment of childhood eczema (BATHE): protocol for multicentre parallel group randomised trial

Santer, Miriam, Rumsby, Kate, Ridd, Matthew J., Francis, Nicholas Andrew ORCID: https://orcid.org/0000-0001-8939-7312, Stuart, Beth, Chorozoglou, Maria, Wood, Wendy, Roberts, Amanda, Thomas, Kim S., Williams, Hywel C. and Little, Paul 2015. Bath additives for the treatment of childhood eczema (BATHE): protocol for multicentre parallel group randomised trial. BMJ Open 5 (10) , e009575. 10.1136/bmjopen-2015-009575

Preview

PDF - Published Version Available under License Creative Commons Attribution. Download (892kB) | Preview

Abstract

Introduction Bath emollients are widely prescribed for childhood eczema, yet evidence of their benefits over direct application of emollients is lacking. Objectives To determine the clinical and cost-effectiveness of adding bath emollient to the standard management of eczema in children Methods and analysis Design: Pragmatic open 2-armed parallel group randomised controlled trial. Setting: General practitioner (GP) practices in England and Wales. Participants: Children aged over 12 months and less than 12 years with eczema, excluding inactive or very mild eczema (5 or less on Nottingham Eczema Severity Scale). Interventions: Children will be randomised to either bath emollients plus standard eczema care or standard eczema care only. Outcome measures: Primary outcome is long-term eczema severity, measured by the Patient-Oriented Eczema Measure (POEM) repeated weekly for 16 weeks. Secondary outcomes include: number of eczema exacerbations resulting in healthcare consultations over 1 year; eczema severity over 1 year; disease-specific and generic quality of life; medication use and healthcare resource use; cost-effectiveness. Aiming to detect a mean difference between groups of 2.0 (SD 7.0) in weekly POEM scores over 16 weeks (significance 0.05, power 0.9), allowing for 20% loss to follow-up, gives a total sample size of 423 children. We will use repeated measures analysis of covariance, or a mixed model, to analyse weekly POEM scores. We will control for possible confounders, including baseline eczema severity and child's age. Cost-effectiveness analysis will be carried out from a National Health Service (NHS) perspective. Ethics and dissemination This protocol was approved by Newcastle and North Tyneside 1 NRES committee 14/NE/0098. Follow-up will be completed in 2017. Findings will be disseminated to participants and carers, the public, dermatology and primary care journals, guideline developers and decision-makers.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Subjects:	R Medicine > RA Public aspects of medicine > RA0421 Public health. Hygiene. Preventive Medicine R Medicine > RJ Pediatrics R Medicine > RL Dermatology
Publisher:	BMJ Publishing Group
ISSN:	2044-6055
Date of First Compliant Deposit:	30 March 2016
Date of Acceptance:	21 August 2015
Last Modified:	05 May 2023 01:52
URI:	https://orca.cardiff.ac.uk/id/eprint/88065

Citation Data

Cited 10 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item